SCHEMBL3673651

SCHEMBL3673651

CCOCCCn1c(O)nc2ncc(Cl)cc21

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
APOBEC3G Q9HC16 1/20 0.38
PDE5A O76074 1/20 0.33
PDE6A P16499 1/20 0.33
HRH4 Q9H3N8 6/20 0.33
ALDH1A1 P00352 3/20 0.33
MAPT P10636 2/20 0.33
HRH3 Q9Y5N1 2/20 0.32
KDM4E B2RXH2 2/20 0.32
HRH1 P35367 1/20 0.32
HTR3A P46098 1/20 0.32
HPGD P15428 1/20 0.32
HTT P42858 1/20 0.32
HSD17B10 Q99714 1/20 0.32
TP53 P04637 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
MYC P01106 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3670195 0.85 KDM4E (0.40) HRH4ALDH1A1MAPTHRH3KDM4E
SCHEMBL3666329 0.84 TLR8 (0.37) HRH4ALDH1A1MAPTHRH3KDM4E
SCHEMBL3668071 0.84 HPGD (0.38) HRH4HRH3KDM4EHTR3AHPGD
SCHEMBL3669424 0.84 PLAU (0.37) APOBEC3GHRH4MAPTHRH3HTR3A
SCHEMBL3667095 0.83 PSEN1 (0.39) HRH4ALDH1A1KDM4E
SCHEMBL3671987 0.81 NUDT1 (0.45) HRH4MAPTHRH3HTR3AHPGD
SCHEMBL3672462 0.80 HRH4 (0.36) HRH4MAPTHRH3HTR3AHPGD
SCHEMBL3675495 0.80 HRH4 (0.41) HRH4HRH3HTR3A
SCHEMBL3675941 0.78 KMT2A (0.42) HRH4HRH3HTR3AHPGDHTT
SCHEMBL3669322 0.77 HSP90B1 (0.37) HRH4HRH3HTR3AHPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851484-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2010-12-14 US claimed
EP-2139478-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS Cytokinetics, Incorporated (US) 2010-01-06 EP claimed
WO-2008121333-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED (US) 2008-10-09 WO claimed
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods CYTOKINETICS, INC. 2008-10-02 US claimed
US-7851484-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2010-12-14 US disclosed
US-7851484-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2010-12-14 US disclosed
US-7851484-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2010-12-14 US disclosed
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods CYTOKINETICS, INC. 2008-10-02 US disclosed
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods CYTOKINETICS, INC. 2008-10-02 US disclosed
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods CYTOKINETICS, INC. 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods TNNC1, TNNI3, TNNT2 APOBEC3G 4537/4885PDE5A 969/4885PDE6A 2308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.